Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 83Terminated 19Unknown 17Active not recruiting 11Recruiting 10Withdrawn 8Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 7Biopsy 6Nivolumab 4Capecitabine 4Bevacizumab 4Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Cyclophosphamide 3Cisplatin 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2decitabine and cedazuridine drug combination 2daratumumab 2Vincristine 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Etoposide 2Epirubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Panitumumab × Clear all
NCT01088620 2013-03-14

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Suspended
134 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡